Novartis’ Afinitor® (everolimus) has been approved by the United States Food and Drug Administration for patients with advanced renal cell carcinoma (RCC) after failure of treatment with Sutent® (sunitinib) or Nexavar® (sorafenib).
Afinitor is a once-daily oral treatment that targets mTOR.
The FDA regulatory filing for Afinitor was based on the results of the Phase III RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily) trial. The trial compared Afinitor to placebo among patients with advanced RCC that had progressed after prior treatment with Sutent, Nexavar, or both sequentially. Afinitor significantly improved progression-free survival.
© 1998-2007 OncoEd.com All Rights Reserved.
These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. All readers should verify all information and data before administering any drug, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Patient Home
